刘毅铭

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Cooley advised Akeso (Hong Kong Stock Exchange code: 9926.HK), a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing and commercializing innovative medicines that address global medical needs, on its HK$1.9 billion (approximately US$250 million) follow-on public offering.

Cooley advised the underwriters of Zhejiang Taimei Medical Technology (Taimei), a digital solution provider focused on the pharmaceutical and medical device industry in China, on its HK$335.1 million initial public offering.

Cooley advised FutureGen Biopharmaceutical, an innovative biopharmaceutical company committed to providing high-quality innovative biologics for patients with cancer, immune diseases and other diseases, on its license agreement with AbbVie to develop FG-M701, a next generation TL1A antibody for the treatment of IBD currently in preclinical development.

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.